Mizuho raised the firm’s price target on BioXcel Therapeutics (BTAI) to $4 from $2 and keeps a Neutral rating on the shares. The firm cites the positive Phase 3 SERENITY At-Home study data for BXCL501 for the target doubling. Mizuho’s risk-adjusted sales estimate for Igalmi in peak year 2037 is now projected at $390M across three indications, from $325M prior. However, the firm sees continued uncertainty around what type of financing BioXcel will undertake to provide more financial stability.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- Sell Rating on Bioxcel Therapeutics Amid Efficacy and Strategic Concerns
- BioXcel Therapeutics Reports Positive Phase 3 Trial Results
- BioXcel reports results from SERENITY At-Home Pivotal Phase 3 safety trial
- BioXcel’s Phase 3 Trial Success for BXCL501
- BioXcel Therapeutics announces SERENITY Phase 3 trial met primary endpoint